Remove Diagnostic Remove Disease Remove Pharmaceutical Remove Radiation
article thumbnail

GE HealthCare Announces Agreement to Acquire MIM Software

Imaging Technology

Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.

article thumbnail

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AuntMinnie 2007: Gadolinium: A 'necessary factor' in the development of NSF?

AuntMinnie

Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. It certainly doesn't help matters that the disease has been linked to gadolinium-based contrast agents, a ubiquitous tool in the MR armamentarium. In 2006 the U.S. Louis hospital.

Disease 116
article thumbnail

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

produced, non-uranium based Mo-99 for use in diagnostic imaging. These capabilities will help them develop and deliver products with the potential to improve care for even more patients with serious disease. “In Our track record of success includes our program to supply U.S.-produced,

Medical 98
article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology.

article thumbnail

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

milla1cf Tue, 07/25/2023 - 20:22 July 25, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers.

article thumbnail

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc.